Communication about high-cost drugs in oncology-the patient view

Annals of Oncology

Volumn 21, Issue 9, 2010, Pages 1910-1914

  Kaser, E ^a   Shaw, J ^b   Marven, M ^c   Swinburne, L ^c   Boyle, F ^a,b,c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Breast Cancer Network Australia   (Australia)

^d Mater Hospital   (Australia)

Author keywords

Communication; Decision making; Drug approval; High cost drugs; Participation; Patient preferences

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; DRUG COST; E-MAIL; EXPERIENCE; FEMALE; HUMAN; INTERPERSONAL COMMUNICATION; INTERVIEW; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ATTITUDE TO HEALTH; AUSTRALIA; BREAST NEOPLASMS; COMMUNICATION; DRUG COSTS; ELECTRONIC MAIL; FEMALE; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; PATIENTS; QUESTIONNAIRES;

EID: 77956138626     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq068     Document Type: Article

References (14)

1. Niezen MG, Stolk EA, Steenhoek A et al. Inequalities in oncology care: economic consequences of high cost drugs. Eur J Cancer 2006; 42(17): 2887-2892.
2. Hall WD, Ward R, Liauw WS et al. Tailoring access to high cost, genetically targeted drugs. Med J Aust 2005; 182(12): 607-608.
3. Thomson J, Schofield P, Mileshkin L et al. Do oncologists discuss expensive anticancer drugs with their patients? Ann Oncol 2006; 17(4): 702-708.
4. Jefford M, Tattersall MH. Informing and involving cancer patients in their own care. Lancet Oncol 2002; 3(10): 629-637.
5. Shepherd HL, Tattersall MH, Butow PN. Physician-identified factors affecting patient participation in reaching treatment decisions. J Clin Oncol 2008; 26(10): 1724-1731.
6. McCaffery KJ, Shepherd HL, Trevena L et al. Shared decision-making in Australia. Z Arztl Fortbild Qualitatssich 2007; 101(4): 205-211.
7. Mileshkin LA, Schofield E, Jefford M et al. To tell or not to tell: the community wants to know about expensive anticancer drugs as a potential treatment option. J Clin Oncol 2009; 27(34): 5830-5837.
8. Simoila R. [Phenomenography-a way to do qualitative research]. Hoitotiede 1993; 5(1): 21-30.
9. Dimoska A, Girgis A, Hansen V et al. Perceived difficulties in consulting with patients and families: a survey of Australian cancer specialists. Med J Aust 2008; 189(11-12): 612-615.
10. Gattellari M, Butow PN, Tattersall MH. Sharing decisions in cancer care. Soc Sci Med 2001; 52(12): 1865-1878.
11. Back A. Patient-physician communication in oncology: what does the evidence show? Oncology (Williston Park) 2006; 20(1): 67-74; discussion 77-78, 83.
12. Bruera E, Willey JS, Palmer JL et al. Treatment decisions for breast carcinoma: patient preferences and physician perceptions. Cancer 2002; 94(7): 2076-2080.
13. Cassileth BR, Zupkis RV, Sutton-Smith K et al. Information and participation preferences among cancer patients. Ann Intern Med 1980; 92(6): 832-836.
14. Fraenkel L, McGraw S. What are the essential elements to enable patient participation in medical decision making? J Gen Intern Med 2007; 22(5): 614-619.